Publications by authors named "D F Claxton"
Article Synopsis
- Cladribine reduces DNA, RNA, and histone methylation and works well with rituximab to treat B-cell lymphomas.
- A phase I study found that combining bortezomib, cladribine, and rituximab is safe and effective for elderly patients with mantle cell lymphoma, with an overall response rate of 84.6%.
- The treatment shows promising outcomes, including high complete remission rates and identified DNA methylation biomarkers that may indicate effective responses.
Chimerism test was evaluated to predict leukemia relapse. Increasing mixed chimerism (IMC), defined as recipient increase ≥0.1% in peripheral blood total cell chimerism, was used as a surrogate of disease activity.
View Article and Find Full Text PDFDrug repurposing is a strategy to discover new therapeutic uses for existing drugs, which have well-established toxicity profiles and are often more affordable. This approach has gained significant attention in recent years due to the high costs and low success rates associated with traditional drug development. Drug repositioning offers a more time- and cost-effective path for identifying new treatments.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the combination of venetoclax (VEN) and vincristine (L-VCR) for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL).
- In a dose escalation trial with 18 patients, the maximum tolerated dose (MTD) of the drug combination was determined to be VEN at 600 mg, with significant adverse events reported in 89% of participants.
- The preliminary results showed a 22% complete response rate, with some patients achieving no measurable residual disease, indicating potential efficacy for this treatment approach.